The James Buchanan Brady Urological Institute
 
 
 

Dr. Kenneth Pienta LABORATORY

OncoFusion Therapeutics

 

OncoFusion Therapeutics, Inc. (Ann Arbor, MI) is an oncology discovery and development company targeting gene fusions that are thought to drive many common cancers.  Cofounders of the company include Shaomeng Wang, PhD, Arul Chinnaiyan, MD, PhD, and Ken Pienta, MD.

In forming a personalized treatment approach, it is critical to identify the specific driving genetic mutation(s) in an individual’s tumor so targeted therapies can be used. OncoFusion’s advances in genome sequencing technology have made it possible to pinpoint the drivers of cancer in a personalized fashion.

OncoFusion will develop therapies for genetically defined cancers, and, more specifically, against targets related to recurrent gene fusions. Gene fusions are often the “driver mutation” in the cancers in which they are found. While the initial focus will be on the four targets  - Bromodomain inhbitors, ERG inhibitors, EZH2-EED inhibitors, and MMSET/NSD2 inhibitors.


oncofusion.com





© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287